Treatment characteristics of combination duv/romi in multicenter R/R cohort
| Treatment characteristics . | All∗ (N = 38) . |
|---|---|
| Pneumocystis jirovecii pneumonia prophylaxis, n (%) | 31 (82) |
| Atovaquone | 12 (32) |
| Trimethoprim-sulfamethoxazole | 21 (55) |
| Varicella zoster virus prophylaxis, n (%) | 32 (84) |
| Acyclovir | 25 (66) |
| Valacyclovir | 8 (21) |
| Valganciclovir | 1 (3) |
| Antifungal prophylaxis, fluconazole, n (%) | 1 (3) |
| Granulocyte colony-stimulating factor, n (%) | 16 (42) |
| Filgrastim | 9 (24) |
| Pegfilgrastim | 7 (18) |
| No. of lead-in duv cycles received by subtype, n (%) | 9 (24) |
| AITL | |
| 1 | 2 (5) |
| 2 | 1 (3) |
| 3 | 1 (3) |
| PTCL-NOS | |
| 3 | 2 (6) |
| 5 | 1 (3) |
| CTCL | |
| 1 | 1 (3) |
| ENKTCL | |
| 1 | 1 (3) |
| No. of lead-in romi cycles received by subtype, n (%) | 2 (5) |
| AITL | |
| 4 | 1 (3) |
| PTCL/CTCL-MF | |
| 4 | 1 (3) |
| No. of combination duv/romi cycles received, median (IQR) | 3 (2-4) |
| nTFH including AITL | 4 (3-5) |
| PTCL-NOS | 2 (2-3) |
| CTCL | 2 (2-3) |
| ALK– ALCL | 4 |
| ENKTCL | 4 |
| ATLL | 3 |
| HSTCL | 2 |
| Duration of combination duv/romi treatment at full/abbreviated doses, median (IQR), mo | 2.9 (1.8-4.1) |
| nTFH including AITL | 3.9 (3.1-4.9) |
| PTCL-NOS | 2.0 (1.3-2.8) |
| CTCL | 1.8 (1.7-3.0) |
| ALK– ALCL | 3.4 |
| ENKTCL | 3.7 |
| ATLL | 2.0 |
| HSTCL | 1.4 |
| Treatment characteristics . | All∗ (N = 38) . |
|---|---|
| Pneumocystis jirovecii pneumonia prophylaxis, n (%) | 31 (82) |
| Atovaquone | 12 (32) |
| Trimethoprim-sulfamethoxazole | 21 (55) |
| Varicella zoster virus prophylaxis, n (%) | 32 (84) |
| Acyclovir | 25 (66) |
| Valacyclovir | 8 (21) |
| Valganciclovir | 1 (3) |
| Antifungal prophylaxis, fluconazole, n (%) | 1 (3) |
| Granulocyte colony-stimulating factor, n (%) | 16 (42) |
| Filgrastim | 9 (24) |
| Pegfilgrastim | 7 (18) |
| No. of lead-in duv cycles received by subtype, n (%) | 9 (24) |
| AITL | |
| 1 | 2 (5) |
| 2 | 1 (3) |
| 3 | 1 (3) |
| PTCL-NOS | |
| 3 | 2 (6) |
| 5 | 1 (3) |
| CTCL | |
| 1 | 1 (3) |
| ENKTCL | |
| 1 | 1 (3) |
| No. of lead-in romi cycles received by subtype, n (%) | 2 (5) |
| AITL | |
| 4 | 1 (3) |
| PTCL/CTCL-MF | |
| 4 | 1 (3) |
| No. of combination duv/romi cycles received, median (IQR) | 3 (2-4) |
| nTFH including AITL | 4 (3-5) |
| PTCL-NOS | 2 (2-3) |
| CTCL | 2 (2-3) |
| ALK– ALCL | 4 |
| ENKTCL | 4 |
| ATLL | 3 |
| HSTCL | 2 |
| Duration of combination duv/romi treatment at full/abbreviated doses, median (IQR), mo | 2.9 (1.8-4.1) |
| nTFH including AITL | 3.9 (3.1-4.9) |
| PTCL-NOS | 2.0 (1.3-2.8) |
| CTCL | 1.8 (1.7-3.0) |
| ALK– ALCL | 3.4 |
| ENKTCL | 3.7 |
| ATLL | 2.0 |
| HSTCL | 1.4 |
Lead-in duv, cycles of combination duv/romi, and duration of treatment were reported in all lines of therapy (N = 38).